Friday, December 30, 2011

Industry view: Changes to business model come slowly to biotech

Entering the fifth year of a funding crisis, biotech’s business model is changing.
New sources of early-stage cash are stepping into the void left by fleeing venture capitalists. But whether those relatively small investments — or corporate venture capital, or grants from disease-specific foundations — are enough to build sustainable companies is an open question.
(San Francisco Business Times subscription required.)

No comments:

Post a Comment